What do systematic reviews say?

Bisphosphonates vs placebo

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Bisphosphonates vs placebo

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Bisphosphonates vs placebo

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Bisphosphonates vs placebo

Bisphosphonates showed no clear difference in number of participants who withdrew due to adverse events compared with placebo (low certainty).

• Bisphosphonates for Paget's disease of bone in adults 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.41, 2.52]
  6 studies · 517 participants
  Low

Bisphosphonates vs placebo/no treatment

Bisphosphonates showed no clear difference in proportion of participants with pain response compared with placebo/no treatment (low certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.15 [0.93, 1.43]
  3 studies · 876 participants
  Low

Bisphosphonates vs placebo/no treatment

Bisphosphonates probably leads to lower skeletal‐related events: any, composite outcome compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.81, 0.94]
  9 studies · 3153 participants
  Moderate

Bisphosphonates vs placebo/no treatment

Bisphosphonates showed no clear difference in mortality compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.91, 1.04]
  9 studies · 2450 participants
  Moderate

Bisphosphonates vs placebo/no treatment

The review found no eligible studies for this question.

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bisphosphonates vs placebo/no treatment

Bisphosphonates showed no clear difference in adverse events: nausea compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.19 [1, 1.41]
  9 studies · 3008 participants
  Moderate

Bisphosphonates vs placebo/no treatment

Bisphosphonates probably leads to higher adverse events: renal compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.65 [1.11, 2.46]
  7 studies · 1794 participants
  Moderate

Bisphosphonates vs placebo/no treatment

It is very uncertain whether bisphosphonates changes adverse events: osteonecrosis of the jaw compared with placebo/no treatment (very low certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 1.92 [0.75, 4.9]
  5 studies · 1626 participants
  Very low

Bisphosphonates vs placebo/no treatment

Bisphosphonates probably leads to lower proportion of participants with disease progression compared with placebo/no treatment (moderate certainty).

• Bisphosphonates for advanced prostate cancer 2017 · Cochrane Headline outcomes only
  RR 0.95 [0.9, 0.99]
  7 studies · 2115 participants
  Moderate

Bisphosphonates vs control

Bisphosphonates leads to lower incident vertebral fractures Radiographic compared with control (high certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 0.57 [0.35, 0.91]
  12 studies · 1343 participants
  High

Bisphosphonates vs control

Bisphosphonates showed no clear difference in incident nonvertebral fractures Radiographic compared with control (low certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 0.79 [0.47, 1.33]
  9 studies · 1245 participants
  Low

Bisphosphonates vs control

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 2042 participants
  Moderate

Bisphosphonates vs control

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  18 studies · 1665 participants
  Moderate

Bisphosphonates vs control

Bisphosphonates showed no clear difference in serious adverse events compared with control (low certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 0.91 [0.74, 1.12]
  15 studies · 1703 participants
  Low

Bisphosphonates vs control

Bisphosphonates showed no clear difference in withdrawals due to adverse events compared with control (low certainty).

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  RR 1.06 [0.77, 1.47]
  15 studies · 1790 participants
  Low

Bisphosphonates vs control

• Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Bisphosphonates vs placebo or no intervention

It is very uncertain whether bisphosphonates changes all‐cause mortality compared with placebo or no intervention (very low certainty).

• Bisphosphonates for osteoporosis in primary biliary cirrhosis 2011 · Cochrane Headline outcomes only
  RD 0
  2 studies · 46 participants
  Very low